Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
This fits the science: BPC-157 uses signaling pathways that stop responding once they reach a certain level
The lyophilized powder is stable at -20C for up to 24 months when stored in sealed, light-resistant containers, giving flexibility for long term research planning
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Timeframe expectations: Minimum 3 months before expecting measurable changes
Coverage policies change frequently, so providers should verify current formulary status with their state Medicaid agency
increasing recovery
US$ 21.71
US$ 25.20
US$ 24.58
US$ 24.11
US$ 23.56
